

1 **Comprehensive genomic, immunological and clinical analysis of**
2 **COVID-19 vaccine breakthrough infections: a prospective,**
3 **comparative cohort study**

4 Di Tian^{*1}, Yang Song^{*2}, Man Zhang^{*3}, Yang Pan^{*3}, Ziruo Ge¹, Yao
5 Zhang¹, Xingxiang Ren¹, Jing Wen¹, Yanli Xu¹, Hong Guo², Peng Yang^{#3},
6 Zhihai Chen^{#1}, Wenbo Xu^{#2}

7 ¹Emergency Department of COVID-19, Beijing Ditan Hospital, Capital
8 Medical University, Beijing, China.

9 ²National Institute for Viral Disease Control and Prevention, Chinese
10 Center for Disease Control and Prevention, Beijing, China.

11 ³Beijing Center for Disease Prevention and Control, Beijing, China.

12

13 Di Tian, Yang Song, Man Zhang, and Yang Pan contributed equally to
14 this work. The author order was determined by their equal but gradated
15 contributions for this paper. Wenbo Xu, Zhihai Chen and Peng Yang
16 contributed equally to this article. The order was determined by the
17 corresponding author after negotiation.

18

19

20

21

22

23 Comprehensive genomic, immunological and clinical analysis of 24 COVID-19 vaccine breakthrough infections: a prospective, 25 comparative cohort study

26

27 Abstract

28 **Objectives:** As the COVID-19 pandemic is still ongoing and
29 SARS-CoV-2 variants are circulating worldwide, an increasing number
30 of breakthrough infections have been detected despite the good efficacy
31 of COVID-19 vaccines.

32 **Methods:** A prospective, comparative cohort study was conducted in
33 Beijing Ditan Hospital to evaluate the clinical, immunological and
34 genomic characteristics of COVID-19 breakthrough infections. Data on
35 88 COVID-19 breakthrough cases (vaccinated group) and 41
36 unvaccinated cases (unvaccinated group) from June 1 to August 20, 2021
37 were extracted from a cloud database. Among these 129 COVID-19 cases,
38 we successfully sequenced 33 whole genomes, including 16 from the
39 vaccinated group and 17 from the unvaccinated group.

40 **Results:** Asymptomatic and mild cases predominated in both groups, but
41 2 patients developed severe disease in the unvaccinated group. Between
42 the two groups, the median time of viral shedding in the vaccinated group
43 were significantly lower than those in the unvaccinated group ($p = 0.003$).
44 A comparison of dynamic IgG titres of cases in the two groups indicated
45 that IgG titres in the vaccinated group showed a significantly increasing
46 trend ($P = 0.028$). The CD4⁺T lymphocyte count was lower in the
47 unvaccinated group, and there was a significant difference between the
48 two groups ($p = 0.018$). In the vaccinated group, the number of moderate
49 cases who received Sinopharm BBIBP (42 cases) was significantly higher
50 than those who received Sinovac Coronavac ($p = 0.020$). Whole-genome

51 sequencing revealed 23 cases of delta variants, including 15 patients from
52 the vaccinated group. However, no significant difference was observed in
53 either the RT-qPCR results or viral shedding time.

54 **Conclusions:** COVID-19 vaccine breakthrough infections were mainly
55 asymptomatic and mild, the IgG titres were significantly higher and
56 increased rapidly, and the viral shedding was short. Delta variants may be
57 more likely to cause breakthrough infections, and vaccination may not
58 reduce the viral loads and shedding time.

59

60 **Key words:** COVID-19; vaccine breakthrough infections; immunological
61 characterization; clinical outcome; whole-genomic analysis; delta variant

62

63

64

65 Introduction

66 Coronavirus disease 2019 (COVID-19) has now become a significant public
67 health concern worldwide. Globally, as of 5:08pm CET, 17 November 2021, there
68 have been 254,256,432 confirmed cases of COVID-19, including 5,112,461 deaths,
69 reported to WHO [1]. Through prevention, control, and treatment, the pandemic
70 situation in China is under control, but there are still local outbreaks and imported
71 cases in some areas.

72 The mainly vaccines in China are inactivated vaccine, adenovirus vector vaccine
73 and recombinant subunit vaccine, of which inactivated vaccine covers the most
74 widely. At least 13 different vaccines (across four platforms) have been administered
75 in China. The first mass vaccination program started in early December 2020. As of
76 14 November 2021, a total of 7,307,892,664 vaccine doses have been administered
77 [1]. COVID-19 vaccines effectively prevent infection, serious illness, and death;
78 however, a fraction of fully vaccinated people still get SARS-CoV-2 infection. An
79 infection that occurs in a fully vaccinated person refers to as a “breakthrough
80 infection” [2]. In the context of widespread vaccine coverage, breakthrough infection
81 has become a new challenge in fighting against COVID-19.

82 The delta variant is currently the predominant variant of the virus in the world.
83 People infected with the delta variant, including fully vaccinated people with
84 symptomatic breakthrough infections, can transmit the virus to others [3]. If delta
85 variants are more likely to cause breakthrough infections, vaccination may reduce the
86 viral loads, and shedding time has become the main topic recently. At present, there
87 are reports of cases of breakthrough infections worldwide, and in China, there were
88 microscopic researches for vaccine breakthrough infections. In the present study, we
89 summarized the clinical data of the patients with breakthrough infections in Beijing
90 Ditan Hospital, compared them with the unvaccinated group, and further analyses the
91 viral genome, clinical and immunological features.

92

93 **Materials and Methods**

94 **Ethical approval.**

95 The study was approved by the Institutional Review Board of Beijing Ditan Hospital,
96 Capital Medical University in Beijing (approval number JDLY2020-020-01).

97 **Study design and recruitment of cases.**

98 Since January 2020, we established the cloud database of COVID-19 patients in
99 Beijing Ditan Hospital, as of 5 October 2021, 802 confirmed cases and 175
100 asymptomatic infections were prospectively analysed. In this study we extracted a
101 total of all 129 adult COVID-19 cases from June to August 2021, and the cases were
102 divided into the breakthrough infection group which were vaccinated with different
103 types of vaccines and the unvaccinated group. COVID-19 patients were diagnosed
104 based on the 8th version of the Diagnosis and Treatment Protocol for Novel
105 Coronavirus Pneumonia Patients[4], and the clinical severity was categorized into 4
106 grades: mild (the clinical symptoms were mild, and there was no evidence of
107 pneumonia on imaging), moderate (fever and respiratory symptoms, imaging
108 manifestations of pneumonia), severe (dyspnoea with a respiratory rate of 30/min,
109 hypoxemia with oxygen saturation of 93%, PaO₂/FiO₂ of 300 mm Hg, if the clinical
110 symptoms had gradually worsened, and the lung imaging showed that the lesions
111 progressed more than 50% within 24 to 48 h), and critical (developed complications,
112 including respiratory failure that needed mechanical ventilation, shock, or other organ
113 failure that needed intensive care unit [ICU] monitoring and treatment).

114 Asymptomatic patients with no clinical symptoms but positive RT-qPCR results were
115 also admitted to the hospital. As of this study, all of the patients have been discharged.

116 **Data collection.** The data of the 129 COVID-19 cases from the two groups were
117 extracted from the cloud database. Medical record reviews of the patients were
118 performed to collect the patients' underlying medical conditions, laboratory test
119 results, and hospital course. In addition, epidemiological data of the patients were

collected. The antibodies levels of all patients were followed up to the 8th week after diagnosis.

Laboratory testing. Oropharyngeal swabs, nasopharyngeal swabs, or sputum specimens obtained from the patients during their hospital stay were collected for RT-qPCR testing. RT-qPCR was conducted using the SARS-CoV-2 nucleic acid test kit (BioGerm, Shanghai, China) with a fluorescence PCR detector following the manufacturers' instructions, and the results were showed as the cycle threshold (Ct) for the ORF1ab and N genes of SARS-CoV-2. Corresponding serum samples were tested for anti-SARS-CoV-2 antibodies using a chemiluminescence immunoassay (CLIA; Bioscience, Chongqing, China).

Whole-genome sequencing and analysis

The selected swab samples of the patients were then sent to the Beijing CDC for further whole-genome sequencing. The viral RNA was extracted using Kingfisher Flex Purification System (ThermoFisher, Waltham, MA, USA), and Libraries were prepared using a Nextera XT Library Prep Kit (Illumina, San Diego, CA, USA), and the resulting DNA libraries were sequenced on a MiniSeq platform (Illumina) using a 300-cycle reagent kit. Mapped assemblies were generated using the SARS-CoV-2 genome (accession number NC_045512) as a reference. Variant calling, genome alignment, and sequence illustrations were generated with CLCBio software.

Whole-genome sequence alignment was conducted using the Muscle tool in MEGA (v7.0). A neighbour-joining phylogenetic tree was constructed using MEGA (v7.0), and the Kimura 2-parameter model with 1,000 bootstrap replicates was used. Genomic lineage designation was performed using the "PANGO lineage" typing method (<https://cov-lineages.org/>).

Statistical analysis. The statistical analyses were performed using SPSS version 25.0 (SPSS IBM, Armonk, NY, USA). From each individual patient, we entered the demographic and clinical variables. Normal continuous variables are represented by the mean and standard deviation. Student's t test was used to test for significant

148 differences. Nonnormally distributed continuous variables are represented by the
149 medians and interquartile ranges, and the Mann-Whitney U test was used for
150 comparisons. Categorical variables are expressed as numbers and percentages, and the
151 chi-squared test and Fisher's exact test were used to compare them. All tests were
152 two-tailed, and statistical significance was defined as a P value lower than 0.05.

153 **Results**

154 **Basic information of the COVID-19 cases**

155 Of the 129 cases, 8 were indigenous cases with one chain of transmission from
156 China, and the remaining 121 were imported cases from outside China (see Table 1).
157 There were 88 cases of breakthrough infection and 41 control cases. There were 61
158 males and 27 females in the vaccinated group and 28 males and 13 females in the
159 unvaccinated group (see Table 2).

160 **Whole-genome sequencing and analysis**

161 Clinical samples from all 129 COVID-19 cases were acquired for further
162 sequencing. Since the viral loads were relatively low in tested samples, a total of 33
163 whole-genome sequences were obtained that had a genome coverage over 98%, and
164 these samples included 16 from the vaccinated group and 17 from the unvaccinated
165 group. After confirming the sequences of the samples by the Pangolin COVID-19
166 Lineage Assigner Web application [5, 6] (<https://pangolin.cog-uk.io/>), the 33 strains
167 contained four kinds of variants, including three kinds of VOCs (alpha, beta and delta
168 variants) and the lineage AZ.2 (sublineage of lineage B.1.1.318, which is currently
169 designated as “alert for further monitoring” by the WHO). Among the 16
170 SARS-CoV-2 strains from the vaccinated group, all strains except one were delta
171 variants, and one sample contained the alpha variant. There were 2 alpha, 2 beta, and
172 8 delta variants in the unvaccinated group, and there were also 5 strains from the
173 lineage AZ.2. The phylogenetic tree showed that most of the strains did not cluster
174 together within the same lineage, which shows that the strains were of different
175 countries of origin (Figure 1). The indigenous cases (indicated by a yellow arrow)
176 clustered together because they were related cases. Furthermore, the strains from
177 AZ.2 were all imported from Greece, and they formed a clade with a high bootstrap
178 value.

179 The numbers of nucleotide mutations (including substitutions, insertions and
180 deletions) of the alpha, beta, delta and AY.2 variants ranged from 53 to 66, 50 to 53,

181 42 to 63 and 67 to 73, respectively. The numbers of amino acid mutations within the
182 spike protein ranged from 11 to 12, 12 to 13, 8 to 15 and 7 to 8, which is suggestive of
183 a high rate of mutation.



185 Figure 1. Neighbor-Joining phylogenetic tree based on the whole genome sequences of the
186 SARS-CoV-2.
187 The strains from the vaccine breakthrough infections are indicated with red font; while the strains
188 from unvaccinated infections are indicated with blue font. The PANGO lineages were marked and
189 colored on the right. The tree was rooted using strain WH04 (EPI_ISL_406801) in accord with the
190 root of PANGO tree.

191

192 **Comparison of the general information and basic laboratory tests in the two** 193 **groups**

194 The median age of the vaccinated group was 33 (26, 38) years, the median age of
195 the unvaccinated group was 30 (23, 43) years, and there was no significant difference
196 between the two groups ($P = 0.276$). Two of the patients from each group had
197 underlying diseases. The average body mass index (BMI) of the vaccinated group was
198 $23.59 \pm 3.75 \text{ kg/m}^2$, and that of the unvaccinated group was $23.46 \pm 4.57 \text{ kg/m}^2$.
199 There was no significant difference between the two groups. There were no
200 differences in sex, age, underlying diseases, or BMI between the two groups (Table
201 1).

202 There were no significant differences in the laboratory tests between the two
203 groups. These laboratory values included the leukocyte count, lymphocyte count,
204 C-reactive protein (CRP) level, serum amyloid A (SAA) level, Alanine
205 aminotransferase (ALT), Aspartate aminotransferase (AST), Creatine kinase (Cr),
206 Prothrombin time (PT), Activated partial thromboplastin time (APTT), Thrombin
207 time (TT) and Fibrinogen (see Table 1). In addition, the average neutrophil count and
208 D-dimer in the unvaccinated group were higher than that in the vaccinated group, but
209 they were all within the normal range.

210 The CD4^+ T lymphocyte count, CD8^+ T lymphocyte count, B lymphocyte count,
211 and NK cell were all lower in the unvaccinated group. The CD4^+ T lymphocyte count
212 was 580 (378.25, 866.75), which was much lower than the breakthrough infections

group (821.84 ± 364.98 cells/ul), and there was a significant difference between the two groups ($p=0.018$) (Table 2).

Comparison of the clinical severity level in the two groups

The two groups' patients were mainly either asymptomatic or mild cases, there were 64 asymptomatic patients and 7 mild patients in the vaccinated group, and there were 25 asymptomatic patients and 5 mild patients in the unvaccinated group. There was no significant difference between the two groups ($P = 0.335$). There were 17 and 9 moderate patients, respectively, and there was no significant difference between the groups ($P = 0.729$). Two patients in the unvaccinated group developed the severe disease (severe or critical), while no severe patients were in the vaccinated group (Table 3).

Comparison of viral shedding time, Ct value, IgM and IgG in the two groups

The median time from complete vaccination to the first positive nucleic acid test was 100.50 (24.00, 171.50) days. The median time of viral shedding was 3.00 (1.00, 11.75) days in the vaccinated group and 11.00 (2.00, 23.50) days in the unvaccinated group. There was a significant difference between the two groups ($P = 0.003$). The viral shedding time was significantly shorter than that of the unvaccinated group. At admission, there were no significant differences between the two groups regarding the median Ct values of the ORF1ab gene and N gene ($P = 0.148$) (Table 4).

There was no significant difference in IgM titres between the two groups ($P = 0.037$). The IgG titre ranged from 0.45 to 393.24 in the vaccinated group, with a median of 21.85 (9.56, 65.35), significantly higher than in the unvaccinated group. There was a significant difference between the two groups ($P = 0.000$) (Table 4). The IgG titres of the 2 severe patients in the unvaccinated group were negative at admission.

Dynamical comparison of the Ct value, IgM and IgG of COVID-19 patients in the two groups

240 The IgM titres in the breakthrough infections declined after reaching peaks
241 during the second week after admission, and the IgM titres increased till the sixth
242 week in the unvaccinated group. The IgM titres were higher in the unvaccinated group,
243 and there was a significant difference between the two groups ($P = 0.012$). The IgG
244 titres in the breakthrough infections gradually increased after admission, and after the
245 fourth week the titres were sharply rose. The IgG titres in breakthrough infections
246 were higher than unvaccinated group at admission and during the whole follow up
247 period, and there was a significant difference between the two groups ($P = 0.004$) (see
248 Fig.2).

249 The Ct values of the ORF1ab gene and the N gene at admission and during the
250 second week, third week, and fourth week after admission gradually increased until
251 negative results in the two groups. There were no significant differences between the
252 two groups ($P=0.740$ and 0.696) (Figure 3).

253 **Comparison of vaccines from different platforms**

254 Among the 88 patients with breakthrough infections, 42 were vaccinated with the
255 Sinopharm BBIBP vaccine, 32 were vaccinated with the Sinovac CoronaVac vaccine,
256 4 were vaccinated with the Pfizer vaccine (BNT162B2), 1 was vaccinated with the
257 AstraZeneca vaccine, 1 was vaccinated with the Sputnik V vaccine, and in 8 patients,
258 the type of vaccine was unknown. We compared two Chinese inactivated vaccines.
259 There were fewer asymptomatic infections and more moderate patients who had the
260 Sinopharm BBIBP vaccine than patients vaccinated with the Sinovac CoronaVac
261 vaccine, and there was a significant difference between the two groups. However, the
262 Ct value, serum antibody titre, and viral shedding time were similar between the
263 groups (see Table 5).

264 **Comparison of the breakthrough infections and unvaccinated group in the** 265 **patients with the delta variant**

266 Among the patients with the delta variant, there were 15 breakthrough infections
267 and 8 patients were unvaccinated. There were no differences in the Ct values of the

268 ORF1ab and N genes between the two groups ($P = 0.857$ and 0.794), and there was no
269 significant difference in the viral shedding time between the two groups ($P = 0.352$).
270 The IgM and IgG titres in patients with breakthrough infections were higher than
271 those without breakthrough infections ($P=0.007$ and $P=0.001$) (see Table 6).
272

273 Table 1. Countries of variant origin in the two groups.

Country of origin	Breakthrough	Unvaccinated
	infections	group
	(n=88)	(n=41)
China	6	2
Russia	1	3
United States of America	4	0
United Kingdom	6	5
Sweden	2	2
Denmark	2	1
Italy	0	1
Greece	0	6
Hungary	1	0
Serbia	4	0
United Arab Emirates	23	12
Philippines	28	9
Lebanon	1	0
Turkmenistan	3	0
Mongolia	2	0
Sudan	1	0
Senegal	1	0
Zimbabwe	2	0
Papa New Guinea	1	0

274

275

276 Table 2. General information and basic laboratory tests in the two groups.

	Breakthrough infections (n=88)	Unvaccinated group (n=41)	P value
Gender			
Male	61	28	0.907
Female	27	13	
Age (years)	33 (26 , 38)	30 (23 , 43)	0.276
≥60 years	2	4	0.153
Underlying diseases	2	2	0.803
BMI (kg/m ²)	23.59±3.75	23.46±4.57	0.882
White blood cell count (x10 ⁹ /L)	7.13±2.04	7.57±2.45	0.285
Neutrophil count (x10 ⁹ /L)	4.41±1.67	5.14±1.95	0.029
Lymphocyte count (x10 ⁹ /L)	2.14±0.82	1.86 (1.40 , 2.22)	0.05
C-reactive protein (mg/L)	0.80 (0.40 , 2.10)	1.30 (0.45 , 3.60)	0.262
Serum amyloid A level (mg/L)	4.80 (3.28 , 8.10)	5.60 (3.05 , 12.88)	0.46
Alanine aminotransferase (U/liter)	24.75 (17, 42.56)	24 (15.7, 33.75)	0.278
Aspartate aminotransferase (U/liter)	20.6 (16.4, 25.48)	18.7(16.85, 24.3)	0.503
Creatine kinase (U/liter)	72.33±16.63	73.15±12.72	0.782
Prothrombin time (s)	11.62±0.83	11.74±0.72	0.432

Activated partial thromboplastin			
time (s)	33.02±3.23	32.72±3.43	0.632
Thrombin time (s)	13.76±1.40	13.93±1.38	0.527
Fibrinogen	291.45±51.01	294.22±64.42	0.794
D-dimer (mg/liter)	0.18 (0.13, 0.25)	0.31 (0.17, 0.43)	<0.001
CD4+T lymphocyte (cells/ul)	821.84±364.98	580 (378.25, 866.75)	0.018
CD8+T lymphocyte (cells/ul)	584.59±270.64	407.5 (321.75, 646)	0.115
B lymphocyte (cells/ul)	327.5 (217.5, 456.5)	264 (163.75, 370)	0.13
NK cell (cells/ul)	240.5(139.75, 338)	176 (119, 278.25)	0.294

277

278 Table 3. Comparisons of the clinical severity levels in the two groups.

	Breakthrough infections (n=88)	Unvaccinated group (n=41)	P value
Asymptomatic patients	64	25	0.179
Mild patients	7	5	0.655
Moderate patients	17	9	0.729
Severe or critical patients	0	2	0.186

279

280 Table 4. Comparison of the viral shedding time, Ct value in the two groups at admission.

	Breakthrough infections (n=88)	Unvaccinated group (n=41)	P value
Time from full vaccination to first	100.50 (24.00 , 171.5)		

positive nucleic acid test (days)			
Viral shedding time (days)	3.00 (1.00 , 11.75)	11.00 (2.00 , 23.50)	0.003
Ct value of the ORF1ab gene	35.75 (31.33 , 37.77)	34.29 (25.46 , 38.03)	0.267
Ct value of the N gene	35.40 (32.80 , 37.40)	34.40 (24.20 , 37.40)	0.148
IgM titre	0.52 (0.14 , 1.12)	0.25 (0.05 , 0.86)	0.037
IgG titre	21.85 (9.56 , 65.35)	2.20 (0.04 , 8.74)	0.000

281

282 Table 5. Comparison of the Sinopharm BBIBP vaccine and the Sinovac CoronaVac vaccine.

	Sinopharm BBIBP (n=42)	Sinovac CoronaVac (n=32)	P value
Asymptomatic patients	25	27	0.020
Mild patients	4	3	1.000
Moderate patients	13	2	0.020
Ct value of the ORF1ab gene	35.80 (32 , 37.22)	36.02 (27.89 , 38.86)	0.495
Ct value of the N gene	34.70 (31.99 , 37.3)	36.33 (28.1 , 37.43)	0.543
IgM titre	0.67 (0.13 , 1.65)	0.45 (0.16 , 1.34)	0.513
IgG titre	32.04 (5.73 , 108.28)	16.19 (9.14 , 22.92)	0.111
Viral shedding time (days)	3.00 (1.00 , 11.50)	3.00 (1.00 , 12.00)	0.699
Time from full vaccination to first positive nucleic acid test (days)	176.79±95.53	23.50 (15.50 , 75.25)	<0.001


283

284

285 Table 6. Comparison of patients with breakthrough infections and controls with the delta variant


	Breakthrough infections with the delta variant (n=15)	Controls with the delta variant (n=8)	P value
Asymptomatic patients	3	2	1.000
Mild patients	4	2	1.000
Moderate patients	8	4	1.000
Ct value of the ORF1ab gene	26.52±6.52	26.05±4.13	0.857
Ct value of the N gene	25.18±6.41	24.44±6.20	0.794
IgM titre	0.22 (0.08, 0.65)	0.05 (0.03, 0.10)	0.007
IgG titre	4.87 (0.93, 38.53)	0.02 (0.02, 0.05)	0.001
Viral shedding time (days)	22.11±5.73	25.5 (25, 26)	0.352

286



287

288



289

290

291

292

293

294

295

296

297

298

299

Figure 2. Dynamic comparison of IgM and IgG titres in COVID-19 patients with breakthrough infections and unvaccinated group.

a. The IgM titres in the breakthrough infections declined after reaching peaks during the second week after admission, and the IgM titres increased till the sixth week in the unvaccinated group. The IgM titres were higher in the unvaccinated group, and there was a significant difference between the two groups ($P = 0.012$). b. The IgG titres in the breakthrough infections gradually increased after admission, and after the fourth week the titres were sharply rose. The IgG titres in breakthrough infections were higher than unvaccinated group, and there was a significant difference between the two groups ($P = 0.004$).




Figure 3. Dynamic comparison of the Ct value of the ORF1ab and N gene in patients with breakthrough infections and unvaccinated group.

a. The Ct values of the ORF1ab gene at admission and during the second week, third week, and fourth week after admission gradually increased, and there was no significant differences between the two groups (P=0.740). b. The Ct values of the N gene at admission and during the second week, third week, and fourth week after admission gradually increased, and there was no significant differences between the two groups (P=0.696).

310 **Discussion**

311 **Breakthrough infections**

312 Some evidence suggests that patients who have recovered from COVID-19 can
313 be reinfected [7-9]; Thus, vaccination may not lead to long-term and effective
314 immunity against SARS-CoV-2 [8].

315 Pediatric patients with COVID-19 may experience milder illness with atypical
316 clinical manifestations. These patients rarely have lymphopenia [10], so we excluded
317 them in this study. We characterized the patients with SARS-CoV-2 breakthrough
318 infections among 88 fully vaccinated patients, six of them had domestically confirmed
319 SARS-CoV-2 strains from China, and the other strains imported from abroad. Most of
320 the patients were either asymptomatic or had a mild case of COVID-19; no patients
321 progressed to severe disease. The Ct values of the ORF1ab gene and the N gene
322 between the patients with breakthrough infections and the unvaccinated group were
323 similar, but the average duration of viral shedding in patients with breakthrough
324 infections was much lower than that in the unvaccinated group. These data indicate
325 that COVID-19 vaccines are still effective at preventing severe illness and death.

326 Similar cases have occurred in other countries. During July 2021, 469 cases of
327 COVID-19 were identified among Massachusetts residents; the vaccination coverage
328 among eligible Massachusetts residents was 69%. Approximately three-quarters (346;
329 74%) of cases occurred in fully vaccinated persons (those patients who had completed
330 a 2-dose course of an mRNA vaccine). The Ct values were similar among the samples
331 from the fully vaccinated patients and the samples from those who were not fully
332 vaccinated [11]. According to Bergwerk et al., 39 breakthrough cases were identified
333 among fully vaccinated health care workers. They concluded that the occurrence of
334 breakthrough infections with SARS-CoV-2 correlated with neutralizing antibody titres
335 during the peri-infection period, and most breakthrough infections were mild or
336 asymptomatic cases [12]. Guangzhou, China, reported 38 imported COVID-19
337 patients who had received inactivated vaccines (Vero cells). Patients infected with

338 SARS-CoV-2 after a vaccination can produce IgG antibodies rapidly in the early stage
339 of disease compared to those who did not receive an inactivated vaccine, and
340 RT-qPCR tests stay negative for a longer period of time [13].

341 **Immunological characteristics.**

342 In this study, the median time from fully vaccinated to positive RT-qPCR was
343 100.5 days, and the median IgG titre of patients with breakthrough infections was
344 21.85 at admission, indicating that the antibodies can still be detected approximately
345 three months after vaccination, and the decrease in the antibody titre may be related to
346 the development of breakthrough infections. The reduction in antibody titre may
347 weaken the protective effect against infection and infectivity. The IgG levels in the
348 vaccination group gradually increased after admission and were significantly higher
349 than that in the unvaccinated group at admission, during the second and the third
350 weeks.

351 The modelling of the data regarding the neutralizing antibody titres and vaccine
352 effectiveness suggested that the neutralizing antibody titre needed to prevent severe
353 illness is lower than the titre required to avoid infection. Although we do not yet know
354 the target titre to prevent infection, it is estimated to be higher than the titre needed to
355 prevent severe illness [14]. Khoury et al. assumed that after eight months following
356 infection, the decay rate would slow down. They modelled the decay rate of the
357 neutralization titre, assuming that it slowed linearly with a 10-year half-life over 1, 1.5,
358 or 2 years (details are presented in their Methods section). Their analysis predicted
359 that even without vaccine boosters, a significant proportion of individuals might
360 maintain a long-term protection from severe infection by an antigenically similar
361 strain, even though these patients may become susceptible to mild disease [15].

362 Vaccine-elicited neutralizing antibody titres correlated with the protective
363 efficacy, suggesting that there was immunity and protection, and the presence of
364 neutralizing antibodies from a prior infection was significantly associated with the
365 protection against reinfection [16,17].

366 Researchers have found a positive correlation between the neutralizing antibody
367 titres and the levels of IgG antibodies. The levels of neutralizing antibodies gradually
368 decrease over for 3 months. Therefore, there is an obvious risk for the possibility of
369 reinfection that is related to the fast decay of antibodies or secondary to a poor
370 elicitation of neutralizing antibodies [18,19].

371 Moreover, our study found that the vaccinated group had higher counts of
372 CD4⁺T lymphocytes, CD8⁺T lymphocytes, B lymphocytes, and NK cells.
373 T-cell-mediated adaptive immune responses are essential for viral clearance and
374 long-term antiviral immunity but may contribute to cytokine storm and could
375 compromise in severe cases of COVID-19 patients due to T-cell exhaustion [20].
376 Successful vaccines should generate SARS-CoV-2-reactive T cells with high
377 specificity for potent immune responses devoid of the undesired effects of
378 inflammation or inception of disease. There are many ongoing vaccine trials, but it is
379 unknown whether they will provide long-lasting protective immunity. Most vaccines
380 are designed to induce antibodies to the SARS-CoV-2 spike protein, but it is unknown
381 if this will be sufficient to induce complete protective immunity to SARS-CoV-2 [21].

382 **Delta variant**

383 In this study, there were 9 breakthrough infections, and 7 unvaccinated patients
384 had the delta variant. Compared with unvaccinated patients, there was no difference in
385 the Ct values between the two groups, and there was no significant difference in viral
386 shedding time between the two groups.

387 The B.1.617.2 (delta) variant was first detected in India in December 2020 and
388 became the most commonly reported variant starting in mid-April 2021 [22].
389 Mutations of the delta variant may have higher replication rates, which leads to higher
390 viral loads and increased transmission rates [23]. Recently, one study reported only a
391 slight difference in the vaccine efficacy against delta variant and alpha variant after
392 patients received two doses of the vaccine [24].

393

394 This study had some limitations. There were relatively few cases in the
395 unvaccinated group, and most patients did not have full genome sequencing results,
396 which may be related to the low viral load (high CT value) in some patients which
397 were tested negative in the origin country. In addition, the number of patients that had
398 breakthrough infections after being vaccinated with non-inactive vaccines was much
399 lower than the number of patients vaccinated with inactive vaccines.

400 Being vaccinated does not mean we can throw caution to the wind and put
401 ourselves and others at risk, mainly because the research is still ongoing into how
402 much vaccines protect against disease, infection, and viral transmission. Therefore,
403 for the foreseeable future, we still need to continue wearing masks and washing our
404 hands, and we need to ensure good indoor ventilation, continue physical distancing,
405 and continue avoiding crowds.

406 **ACKNOWLEDGMENTS**

407 We thank all physicians who participated in the management of these COVID-19
408 cases. This study was funded by Chang Jiang Scholars program (grant no.2019077).
409 W.X., Z.C. conceived the study, W.X., Z.C. designed the study, Z.C. and W.X. and
410 P.Y. maintained the database for data collection, Z.C., W.X. supervised the data
411 collection, D.T., Y.S., M.Z., Y.P., Z.G., Y.Z., X.R., J.W. and Y.X. interpreted the data,
412 D.T., Y.S. and M.Z. did the statistical analysis, D.T. prepared the manuscript, D.T.,
413 Y.S., M.Z. and Z.G. wrote the manuscript, D.T. and Z.G. prepared the figures, M.Z.
414 and Y.P. and P.Y. did the COVID-19 specimen processing and sequencing, and all
415 authors reviewed and approved the final version of the manuscript. Z.C., W.X., and
416 P.Y. are the guarantors.
417 We declare no conflicts of interest.

418 **References**

- 419 1. <https://covid19.who.int>
- 420 2. <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/effectiveness/why-measure-effectiveness/breakthrough-cases.html>
- 421 3. <https://www.cdc.gov/coronavirus/2019-ncov/variants/delta-variant.html>
- 422 4. National Health Commission of the People's Republic of China. Diagnosis and
- 423 treatment plan for COVID-19(trial version 8 revision). Chinese Journal of Clinical
- 424 Infectious Diseases, 2021,14(2):81-88.
- 425 5. Brown CM, Vostok J, Johnson H, et al. Outbreak of SARS-CoV-2 Infections,
- 426 Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public
- 427 Gatherings - Barnstable County, Massachusetts, July 2021. *MMWR Morb Mortal*
- 428 *Wkly Rep.* 2021;70(31):1059-1062. Published 2021 Aug 6.
- 429 doi:10.15585/mmwr.mm7031e2
- 430 6. Bergwerk M, Gonen T, Lustig Y, et al. Covid-19 Breakthrough Infections in
- 431 Vaccinated Health Care Workers [published online ahead of print, 2021 Jul 28]. *N*
- 432 *Engl J Med.* 2021;NEJMoa2109072. doi:10.1056/NEJMoa2109072
- 433 7. To KK, Hung IF, Ip JD, et al. COVID-19 re-infection by a phylogenetically distinct
- 434 SARS-coronavirus-2 strain confirmed by whole genome sequencing [published online
- 435 ahead of print, 2020 Aug 25]. *Clin Infect Dis.* 2020;ciaa1275.
- 436 doi:10.1093/cid/ciaa1275
- 437 8. Nainu F, Abidin RS, Bahar MA, et al. SARS-CoV-2 reinfection and implications
- 438 for vaccine development. *Hum VaccinImmunother.* 2020;16(12):3061-3073.
- 439 doi:10.1080/21645515.2020.1830683
- 440 9. Hosseini SA, Zahedipour F, Mirzaei H, KazemiOskuee R. Potential SARS-CoV-2
- 441 vaccines: Concept, progress, and challenges. *Int Immunopharmacol.* 2021;97:107622.
- 442 doi:10.1016/j.intimp.2021.107622
- 443

- 444 10. Cui X, Zhao Z, Zhang T, et al. A systematic review and meta-analysis of children
445 with coronavirus disease 2019 (COVID-19). *J Med Virol.* 2021;93(2):1057-1069.
446 doi:10.1002/jmv.26398
- 447 11. Gupta V, Bhoyar RC, Jain A, et al. Asymptomatic reinfection in two healthcare
448 workers from India with genetically distinct SARS-CoV-2 [published online ahead of
449 print, 2020 Sep 23]. *Clin Infect Dis.* 2020;ciaa1451. doi:10.1093/cid/ciaa1451
- 450 12. Chen M, Zhou YM, Peng H, et al. Clinical characteristics of imported COVID-19
451 patients after inoculating inactivated vaccine[J]. *Chinese Journal of Infection Control*,
452 2021,20(7):586-591. DOI:10.12138/j.issn.1671-9638.20211352.
- 453 13. Jia Z, Gong W. Will Mutations in the Spike Protein of SARS-CoV-2 Lead to the
454 Failure of COVID-19 Vaccines? *J Korean Med Sci.* 2021;36(18):e124. Published
455 2021 May 10. doi:10.3346/jkms.2021.36.e124
- 456 14. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly
457 predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat Med.*
458 2021;27(7):1205-1211. doi:10.1038/s41591-021-01377-8
- 459 15. Yu J, Tostanoski LH, Peter L, et al. DNA vaccine protection against SARS-CoV-2
460 in rhesus macaques. *Science.* 2020;369(6505):806-811. doi:10.1126/science.abc6284
- 461 16. Addetia A, Crawford KHD, Dingens A, et al. Neutralizing Antibodies Correlate
462 with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with
463 a High Attack Rate. *J Clin Microbiol.* 2020;58(11):e02107-20. Published 2020 Oct 21.
464 doi:10.1128/JCM.02107-20
- 465 17. Carrillo J, Izquierdo-Useros N, Ávila-Nieto C, Pradenas E, Clotet B, Blanco J.
466 Humoral immune responses and neutralizing antibodies against SARS-CoV-2;
467 implications in pathogenesis and protective immunity. *Biochem Biophys Res Commun.*
468 2021;538:187-191. doi:10.1016/j.bbrc.2020.10.108
- 469 18. Wang K, Long QX, Deng HJ, et al. Longitudinal Dynamics of the Neutralizing
470 Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2

471 (SARS-CoV-2) Infection. *Clin Infect Dis*. 2021;73(3):e531-e539.
472 doi:10.1093/cid/ciaa1143

473 19. Toor SM, Saleh R, Sasidharan Nair V, Taha RZ, Elkord E. T-cell responses and
474 therapies against SARS-CoV-2 infection. *Immunology*. 2021;162(1):30-43.
475 doi:10.1111/imm.13262

476 20. Peng Y, Mentzer AJ, Liu G, et al. Broad and strong memory CD4+ and CD8+ T
477 cells induced by SARS-CoV-2 in UK convalescent individuals following
478 COVID-19. *Nat Immunol*. 2020;21(11):1336-1345. doi:10.1038/s41590-020-0782-6

479 21. Sahin U, Muik A, Derhovanessian E, et al. COVID-19 vaccine BNT162b1 elicits
480 human antibody and TH1 T cell responses [published correction appears in *Nature*.
481 2021 Feb;590(7844):E17]. *Nature*. 2020;586(7830):594-599.
482 doi:10.1038/s41586-020-2814-7

483 22. European Centre for Disease Prevention and Control. Threat assessment brief:
484 emergence of SARS-CoV-2 B.1.617 variants in India and situation in the EU/EEA.
485 May 11, 2021 (<https://www.ecdc.europa.eu/en/publications-data/threat-assessment-emergence-sars-cov-2-b1617-variants>).
486

487 23. Johnson BA, Xie X, Kalveram B, et al. Furin cleavage site is key to SARS-CoV-2
488 pathogenesis. August 26, 2020 (<https://www.biorxiv.org/content/10.1101/2020.08.26.268854v1>). preprint.
489

490 24. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 Vaccines
491 against the B.1.617.2 (Delta) Variant. *N Engl J Med*. 2021;385(7):585-594.
492 doi:10.1056/NEJMoa2108891